Sanofi SA's Genzyme Enter into Cross-license Agreement with Asklepios BioPharmaceutical Inc-M2 Pharma


Tuesday, 16 Jul 2013 08:00pm EDT 

M2 Pharma reported that Asklepios BioPharmaceutical Inc (AskBio), a private clinical-stage biotechnology company, announced on the signing of a non-exclusive cross-license agreement with Sanofi SA's Genzyme. Under the agreement, Genzyme receives rights to AskBio's Duplex gene therapy vector technology for its internal product development and external sublicensing. Also, under this agreement, AskBio receives rights to Genzyme's Intra-Strand Base-Pairing technology, which also supports packaging of DNA double-stranded genomes within an AAV-based gene therapy vector. Reportedly, the rights obtained from Genzyme by AskBio strengthen and broaden the basis with which AskBio may continue its use and sub-license of Duplex vectors for internal clinical development, as well as external partnerships and collaborations. 

Company Quote

75.38
-0.79 -1.04%
19 Dec 2014